Please use this identifier to cite or link to this item:
Title: Benefit-risk assessment of orlistat in the treatment of obesity.
Austin Authors: Sumithran, Priya ;Proietto, Joseph 
Affiliation: Department of Medicine (Austin Health), University of Melbourne, Heidelberg Repatriation Hospital, Heidelberg, VIC, 3081, Australia,
Issue Date: 1-Aug-2014
Publication information: Drug Safety; 37(8): 597-608
Abstract: Orlistat, an inhibitor of intestinal lipase, has been available for the treatment of obesity for nearly two decades. In conjunction with a hypocaloric diet, orlistat treatment results in a placebo-subtracted reduction in body weight of around 3 kg at 1 year, and increases the likelihood of achieving clinically significant (≥5%) weight loss by around 20%. Orlistat-induced weight loss also confers modest improvements in systolic and diastolic blood pressure, low-density lipoprotein (LDL) cholesterol, glycemic parameters, and progression to diabetes in people with impaired glucose tolerance. Overall, it has a good safety profile, and serious adverse events (including reports of severe kidney and liver injury) are rare. However, a high rate of gastrointestinal side effects limits adherence to treatment.
Gov't Doc #: 25064699
DOI: 10.1007/s40264-014-0210-7
Type: Journal Article
Subjects: Anti-Obesity Agents.adverse effects.pharmacology.therapeutic use
Body Weight.drug effects
Gastrointestinal Diseases.chemically induced
Lactones.adverse effects.pharmacology.therapeutic use
Medication Adherence
Obesity.drug therapy
Risk Assessment
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
25064699.pdf70.52 kBAdobe PDFView/Open
Show full item record

Page view(s)

checked on Nov 25, 2022


checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.